# Imaging FDG Flare in Melanoma

> **NCT02791594** · — · COMPLETED · sponsor: **Abramson Cancer Center at Penn Medicine** · enrollment: 21 (actual)

## Conditions studied

- Metastatic Melanoma

## Interventions

- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT02791594
- **Lead sponsor:** Abramson Cancer Center at Penn Medicine
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06
- **Primary completion:** 2020-07-01
- **Final completion:** 2020-07-01
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2024-11-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02791594

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02791594, "Imaging FDG Flare in Melanoma". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT02791594. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*